GGSK将投资30B美元用于美国设施和研发;Merck和AstraZeneca在商业挑战方面削减英国的计划规模。 GSK to invest $30B in U.S. facilities and R&D; Merck and AstraZeneca scale back UK plans over business challenges.

GlaxoSmithKline计划在美国五年内投资至少300亿美元,以扩大制造和研发,包括新的生物设施和数字技术升级。 GlaxoSmithKline plans to invest at least $30 billion in the U.S. over five years to expand manufacturing and R&D, including new biologics facilities and digital technology upgrades. 默克(Merck)的英国老板说, 该国的制药环境是“困难”且需要改善, 指出做终端到终端业务的挑战是取消10亿英镑伦敦网站的一个因素。 Meanwhile, Merck's UK boss said the country's pharmaceutical environment is "difficult" and needs improvement, citing challenges in doing end-to-end business as a factor in canceling a £1 billion London site. 这是在AstraZeneca暂停了2亿英的剑桥研究投资之后. This follows AstraZeneca pausing a £200 million Cambridge research investment. 两家公司都报告正在与联合王国政府进行会谈,但强调需要采取更多行动支持创新和投资。 Both companies report ongoing talks with the UK government but stress the need for more action to support innovation and investment.